Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Magnolia Capital Advisors LLC

Magnolia Capital Advisors LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,198 shares of the medical research company’s stock after purchasing an additional 553 shares during the period. Magnolia Capital Advisors LLC’s holdings in Edwards Lifesciences were worth $533,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Harbor Capital Advisors Inc. raised its holdings in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock valued at $824,000 after acquiring an additional 273 shares during the last quarter. Nordea Investment Management AB raised its holdings in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock valued at $301,355,000 after acquiring an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its holdings in Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock valued at $355,344,000 after acquiring an additional 300,000 shares during the last quarter. Avanza Fonder AB acquired a new position in Edwards Lifesciences in the 4th quarter valued at $4,845,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Edwards Lifesciences by 9.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 478,418 shares of the medical research company’s stock valued at $31,571,000 after acquiring an additional 40,348 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 1.1 %

NYSE:EW opened at $72.41 on Monday. The company has a market capitalization of $42.71 billion, a price-to-earnings ratio of 10.45, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The stock has a 50-day simple moving average of $72.49 and a 200 day simple moving average of $69.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,000 shares of company stock worth $2,195,180. Corporate insiders own 1.27% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several analyst reports. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price target for the company from $82.00 to $90.00 in a report on Monday, December 16th. Robert W. Baird dropped their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Barclays upped their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a report on Monday, December 2nd. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Finally, JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.